Thu, May 15, 11:37 AM (59 days ago)
**Abeona Therapeutics Inc. (ABEO) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $0 (no revenue generated in Q1 2025). - **Net Loss:** $12.0 million (Q1 2025) vs. $31.6 million (Q1 2024). - **Operating Expenses:** $19.7 million (Q1 2025) vs. $14.3 million (Q1 2024). - **Research & Development:** $9.9 million (Q1 2025) vs. $7.2 million (Q1 2024). - **General & Administrative:** $9.8 million (Q1 2025) vs. $7.1 million (Q1 2024). - **Cash Flow:** Net decrease of $7.4 million (Q1 2025) vs. net increase of $3.1 million (Q1 2024). - **Cash & Equivalents:** $16.3 million (Q1 2025) vs. $17.9 million (Q1 2024). **Key Metrics & Trends:** - **Profit Margins:** Negative, with significant operating losses. - **Earnings Changes:** Improved net loss by $19.6 million compared to Q1 2024. - **Future Operations Impact:** Positive with FDA approval of ZEVASKYN™ and planned commercial launch in Q3 2025. **Uncertainties & Future Outlook:** - **Liquidity:** Adequate for the next 12 months with $84.5 million in cash resources and additional proceeds from PRV sale. - **Regulatory:** FDA approval of ZEVASKYN™ and ongoing clinical trials for other product candidates. - **Market:** Potential market for ZEVASKYN™ and other gene therapies, but subject to regulatory and commercialization risks. **Notable Events:** - FDA approval of ZEVASKYN™ on April 28, 2025. - Sale of Rare Pediatric Disease Priority Review Voucher for $155 million. - Activation of the first Qualified Treatment Center for ZEVASKYN™. **Ticker:** ABEO